|
Brussels, Belgium
June 25, 2009
At its Annual General Assembly
held June 24th in Brussels,
EuropaBio, the European Association for Bioindustries,
elected Dr. Andrea Rappagliosi (1) Vice President European
Government Affairs & Head of Brussels Office, GlaxoSmithKline,
to Chair the Association over the next two years. He succeeds
Mr. Steen Riisgaard, President and CEO, Novozymes A/S , who has
completed his mandate but will stay on as a Board Member.
Dr. Andrea Rappagliosi joined the EuropaBio Board in 2004 and
was appointed at the Executive Committee in 2005. In the last
four years, he chaired the Healthcare Council of the Association
and represented EuropaBio at the European Commission High Level
Pharmaceutical Forum.
“We need to be courageous and drive changes to ensure that in
Europe we utilize the full potential of biotechnology in order
to overcome the important challenges imposed by the financial,
economic and social crisis that we are currently facing” – says
Dr. Andrea Rappagliosi, Chairman of EuropaBio – “By
strengthening the European biotechnology sector's
competitiveness, we will build a solid foundation for a wealthy
and healthy society in Europe, where citizens can live better
and longer. This sector can play an important part in progress
towards Europe’s goal of economic growth, social prosperity and
solidarity.”.
In welcoming the new chairman, Mr. Willy De Greef, Secretary
General of EuropaBio said: “We are delighted to have a strong
believer in our industry who will continue to bring his passion
to the cause of biotechnology. Andrea will be a dynamic Chairman
and will build further on the strengths of the association.”
In addition to new Board Members (2), the association also
elected Mr. Thomas Bols, Director Government Affairs, Europe,
Amgen, as Chair of the Healthcare Council and Dr. Detlef Niese,
Head of External Affairs, Global Development, Novartis, as
Vice-Chair for Science. Additionally, Mr. Jan Wisse, Managing
Director of the Netherlands' Biotech Industry Association
(NIABA), was elected Chair of the National Associations’
Council.
EuropaBio is the EU association representing the biotechnology
industry across a wide number of industrial sectors (3),
including health, agri-food and industrial processes. The
association has been at the forefront of developing policies to
grow a strong biotechnology sector in Europe.
(1) Biography of Andrea Rappagliosi
Born in Rome, Andrea Rappagliosi received a law degree from the
University of Rome “La Sapienza” and completed a post-graduate
Masters at the Istituto Superiore dei Studi Legislativi (ISLE)
from which he obtained a “Legislative Consultant Diploma”.
He began his career in the early eighties, first in the Italian
Government as a member of staff for the State Undersecretary of
the Treasury, then for the Italian Senate focused on drafting of
legislative texts, comparative legal studies and public budget
analysis.
In 1992, he moved into healthcare and worked for The Ares-Serono
Group as Head of the Institutional Affairs Department in charge
of the Rome and Brussels offices. From 1995 to 1999, he was
Public Affairs Director at Baxter Healthcare, part of the
European Public Affairs team. In 1999, he returned to Serono
International, today Merck Serono International, as Vice
President Health Policy & Market Access Europe.
In April 2009, Andrea joined GlaxoSmithKline as Vice President
European Government Affairs & Head of Brussels Office.
- From 2005 to 2008, he has been member of the European
Commission High Level Pharmaceutical Forum representing
EuropaBio, the European Association for Bioindustry.
- He sits on the Board of the Foundation of the European
Platform for Patients Organizations, Science & Industry
(EPPOSI).
- He is member of HTAi (the International Society of Health
Technology Assessment) and founding member of its Policy Forum.
- He has been Industry representative at the EMEA/COMP (European
Medicines Evaluation Agency/ Committee for Orphan Medicinal
Products) Working Group with Interested Parties in the first two
terms 2000 to 2005.
- He is member of the British Institute of International and
Comparative Law and is a member of the Editorial Board of the
Journal of Commercial Biotechnology.
(2) New EuropaBio Board of Management (as of June 24h 2009) -
http://www.europabio.org/eu_board.htm
(3) EuropaBio Members Listing -
http://www.europabio.org/eu_membership.htm
EuropaBio's mission is to promote an innovative and dynamic
biotechnology-based industry in Europe. EuropaBio, (the European
Association for Bioindustries), has 68 corporate and 7 associate
members operating worldwide, 4 Bioregions and 25 national
biotechnology associations representing some 1800 small and
medium sized enterprises. |
|
